BMY Stock Recent News

Want to buy a good dividend stock and secure a great price in the process? I have a list of three stocks that can help you diversify your portfolio, allow you to earn above-average dividends, and score some potential bargains in the process.

Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.

BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to value/ defensive stocks. This is significantly aided by the double beat FQ4'24 performance and the decent FY2025 guidance, as the management drives renewed growth through new portfolios and M&A activities. Despite the higher net debts on balance sheet, we believe that BMY's dividends remain safe as observed in the richer cash flows and recent payout raise.

Merck and Bristol-Myers Squibb occupy leading positions in the cancer therapy market. Each of them has advantages, as well as dark spots in the portfolio of medications relative to the comparator. In this article, dear Seeking Alpha readers, you will learn whether Merck or Bristol-Myers Squibb is a more promising stock in the long term.

Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons it is home to solid dividend stocks, including Pfizer (PFE -0.49%) and Bristol Myers Squibb (BMY 0.23%), two of the leading pharmaceutical companies in the world.

Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciation has contributed 68%.

Bristol Myers Squibb (BMY) reachead $60.08 at the closing of the latest trading day, reflecting a +0.3% change compared to its last close.

I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.

I reiterate my "Buy" rating on Bristol-Myers Squibb due to its undervaluation, strong growth portfolio, and significant cost-saving initiatives. BMY's drug portfolio expansion and strategic productivity initiatives are expected to sustain high EBITDA margins and drive future top-line growth. Despite legacy drug challenges, BMY's growth portfolio shows robust revenue acceleration, with a projected fair value per share of $70.35, offering a 17.25% upside.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of 2seventy will receive $5.00 in cash for each share of 2seventy that they own. KSF is seeking to determine whether this consideration and the process that led to.